Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

EU is first to approve Sanofi and Regeneron's Dupixent for COPD, ending a 10-year hiatus in new therapies.

GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD if it gets approved by the FDA.

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product ...

GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May ...

Latest medical research on lung disease. Learn about the symptoms of chronic obstructive pulmonary disease (COPD), emphysema, and lung cancer along with the latest treatment information.